Proteolysis targeting chimera as well as preparation method, pharmaceutical composition and application thereof

By modifying the CDK4/6 inhibitor Ribociclib and combining it with CRBN ligands, a PROTAC molecule targeting CDK2/4/6/9 was synthesized. This solved the problems of selectivity and large molecular weight of existing PROTAC molecules in the treatment of CRPC, and achieved efficient targeted degradation of CDK2/4/6/9 and effective treatment of prostate cancer.

CN119019406AActive Publication Date: 2024-11-26HEBEI KANGTAI PHARMA

Patent Information

Application Number
CN202411111541.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-14
Publication Date
2024-11-26
Estimated Expiration
2044-08-14

AI Technical Summary

Technical Problem

Existing PROTAC molecules suffer from poor selectivity, large molecular weight, and high polar surface area in the treatment of castration-resistant prostate cancer (CRPC), resulting in poor treatment efficacy.

Method used

By modifying the selective CDK4/6 inhibitor Ribociclib and combining it with the CRBN ligand thalidomide, a series of proteolytic targeted chimeras (PROTACs) targeting CDK2/4/6/9 were designed and synthesized. The proteolytic targeted chimera technology was used to achieve efficient targeted degradation of CDK2/4/6/9.

Benefits of technology

The synthesized compound A12 showed significant CDK2/4/6/9 protein degradation effects with high selectivity and demonstrated good therapeutic effects on prostate cancer in in vivo animal models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019406A_ABST
    Figure CN119019406A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of chemical medicine synthesis, and particularly relates to a proteolysis targeting chimera as well as a preparation method, a pharmaceutical composition and application thereof. The structural formula of the proteolysis targeting chimera is shown as a formula Ia or a formula Ib; the preparation process is simple and easy to implement, and the prepared proteolysis targeted chimera or the pharmaceutically acceptable salt thereof has the effect of efficiently degrading CDK2 / 4 / 6 / 9 in a targeted manner and has relatively high selectivity; experimental results show that the compound can utilize a ubiquitin-proteasome system to induce targeted degradation of CDK2 / 4 / 6 / 9 protein and inhibit downstream signal channels of the protein, selective degradation of the CDK2 / 4 / 6 / 9 is achieved on the protein level, the cell level and the animal level, and the compound has a good effect of resisting prostate cancer cell proliferation. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of chemical drug synthesis, and specifically relates to a protein hydrolysis targeting chimera and a preparation method, a pharmaceutical composition and use thereof. Background Art

[0002] Castration-resistant prostate cancer (CRPC) is the main type of cancer that causes death in prostate cancer patients. The persistent action of androgen receptor (AR) makes CRPC patients insensitive to traditional and novel endocrine therapy drugs targeting the AR signaling axis. Cyclin-dependent kinases (CDKs) and cyclin partners coordinately regulate cell cycle progression and transcription. Several studies have shown that multiple CDKs have direct interactions with AR. Androgens, which are closely related to the occurrence and progression of prostate cancer (PCa), can overactivate cell cycle-related CDK4 / 6, stimulate its overexpression, and reduce the sensitivity of CDKs inhibitors. In metastatic castration-resistant prostate cancer (mCRPC), c-Myc expression is often upregulated, and CDK4 / 6 is a direct transcriptional target of c-Myc. CDK2 and CDK4 / 6 have synergistic effects, and CDK2 can also mediate AR phosphorylation. In addition, studies have shown that CDK9 is also directly related to AR and can mediate AR phosphorylation. Phosphorylation of serine 81 (S81) on AR may play an important role in regulating the core functions of AR. Therefore, CDK2 / 4 / 6 / 9 may be a potential target for the treatment of CRPC driven by the AR signaling axis.

[0003] Proteolysis targeting chimeras (PROTACs) are emerging drug development technologies that use the ubiquitin-proteasome system (UPS) to achieve target protein degradation and clearance. Due to the "event-driven mechanism", PROTACs have the advantages of targeting undruggable proteins, overcoming drug resistance, and low dosage, which provides new ideas for current drug research and development. However, the clinical progress of various PROT AC molecules is not smooth at present. Most PROTAC molecules do not meet the drug-like 5 principles and have higher molecular weights and larger polar surface areas. Summary of the invention

[0004] The present invention utilizes the proteolysis targeted chimera (PROTACs) technology to modify the selective CDK4 / 6 inhibitor Ribociclib through molecule-protein docking analysis, and then connects the CRBN ligand (i.e., thalidomide) through a specific rigid Linker molecule to obtain a series of PROTAC molecules targeting CDK2 / 4 / 6 / 9, whose structural formula is shown in Formula Ia or Formula Ib:

[0005] The linker in the formula Ia is any one of the following structures:

[0006]

[0007] The Linker in Formula Ib is any one of the following structures:

[0008]

[0009] The present invention found that the synthesized proteolysis targeting chimeric compounds have a significant effect of inducing CDK2 / 4 / 6 / 9 protein degradation, especially the compound A12 shown below, which has a more prominent effect.

[0010]

[0011] The second aspect of the present invention further provides a method for preparing the above-mentioned compound A12, and its synthetic route is as follows:

[0012]

[0013] The third aspect of the present invention is to provide the use of the above-mentioned proteolysis targeting chimera or its solvate or pharmaceutically acceptable salt in the preparation of drugs for treating and / or preventing CDK2 / 4 / 6 / 9 related diseases, including cancer, especially prostate cancer, more especially castration-resistant prostate cancer.

[0014] In a fourth aspect of the present invention, a pharmaceutical composition is provided, wherein the main active ingredient is the above-mentioned proteolysis targeting chimera or a pharmaceutically acceptable salt thereof. According to the needs of the actual situation, the dosage form of the pharmaceutical composition can be a liquid preparation or a solid preparation, such as one of tablets, capsules, powders, granules, pills, pastes and powders. The pharmaceutical composition may also include one or more pharmaceutically acceptable excipients or carriers, such as at least one of carbohydrates, polymers, lipids and minerals.

[0015] The beneficial effects of the present invention are as follows: the proteolysis targeting chimera proposed in the present invention has the effect of efficiently targeting and degrading CDK2 / 4 / 6 / 9, has high selectivity, and has achieved good therapeutic effects in in vivo animal models, providing a new means for treating and / or preventing CDK2 / 4 / 6 / 9 related diseases, especially prostate cancer. DETAILED DESCRIPTION

[0016] The following will be combined with the embodiments to clearly and completely describe the concept and technical effects of the present invention, so as to fully understand the purpose, scheme and effect of the present invention. It should be noted that the embodiments and features in the embodiments of this application can be combined with each other without conflict.

[0017] Example 1

[0018] A proteolysis targeting chimera (Compound A1), the synthesis route of which is as follows:

[0019]

[0020] The specific process is:

[0021] (1) Specific preparation process of intermediate 11a:

[0022]

[0023] Compound 10a (3.70 g, 8.86 mmol, 1.0 eq) was dissolved in 90 mL MeOH, 10% palladium carbon (350 mg) was added, argon was purged five times, and then hydrogen was replaced five times. The reaction was allowed to proceed overnight at room temperature under a hydrogen atmosphere, and the reaction progress was monitored by TLC (PE: EA = 1: 1). After the reaction was complete, palladium carbon was filtered off with diatomaceous earth, and the filtrate was concentrated under reduced pressure to obtain compound 11a (white solid, 2.46 g, 98%). HRMS (ESI) predicted value C 15 H 30 N3O2 + [M+H] + : 284.2333, measured value: 284.2339.

[0024] (2) Specific preparation process of intermediate 12a:

[0025]

[0026] Compound 7a (500 mg, 1.81 mmol, 1.0 eq) was dissolved in 10 mL DMSO, and compound 11a (513 mg, 1.81 mmol, 1.0 eq) and N,N-diisopropylethylamine (702 mg, 5.43 mmol, 3.0 eq) were added. The mixture was reacted overnight at 90 °C, and the reaction progress was monitored by TLC (DCM: MeOH = 18: 1). After the reaction was complete, the system was cooled to room temperature, and 30 mL of water was added to precipitate solids. The solids were filtered with filter paper, and the filter cake was purified by silica gel column chromatography (DCM: MeOH = 40: 1) to obtain compound 12a (yellow solid, 791 mg, 81%). HRMS (ESI) predicted value C 28 H 38 N5O6 + [M+H] + :540.2817, measured value:540.2820.

[0027] (3) Specific preparation process of compound A1:

[0028]

[0029] Compound 12a (300 mg, 0.56 mmol, 1.05 eq) was placed in a reaction flask, 4 mL of 4M hydrochloric acid / 1,4-dioxane solution was added, the reaction was continued at room temperature for 30 min, the Boc protecting group was removed, TLC was monitored, and the reaction was concentrated and dried for later use after completion. Compound 4 (208 mg, 0.53 mmol, 1.0 eq) was dissolved in 6 mL of N,N-dimethylformamide, HATU (242 mg, 0.64 mmol, 1.2 eq) and N,N-diisopropylethylamine (137 mg, 1.06 mmol, 2.0 eq) were added, and the mixture was stirred for 15 min. Subsequently, the Boc-removed 12a was added to the reaction system, and the reaction was continued overnight at room temperature, and TLC was monitored (DCM: MeOH = 15: 1). After the reaction was complete, 15 mL of water was added to the system, extracted with EA (10 mL × 3), the organic phase was collected, and back-extracted with saturated sodium chloride solution (10 mL × 3). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, and purified by silica gel column chromatography (DCM: MeOH = 45: 1) to obtain compound A1 (yellow solid, 226 mg, 50%). HRMS (ESI) predicted value C 44 H 51 N 10 O6 + [M+H] + :815.3988, measured value:815.3972.

[0030] Example 2

[0031] A proteolysis targeting chimera (Compound A2), the synthesis route of which is as follows:

[0032]

[0033] The specific process is:

[0034] (1) Specific preparation process of intermediate 13a:

[0035]

[0036] Compound 4 (1.00 g, 2.55 mmol, 1.0 eq) was dissolved in 25 mL of acetonitrile, HATU (1.16 g, 3.05 mmol, 1.2 eq) and N,N-diisopropylethylamine (658 mg, 5.075 mmol, 2.0 eq) were added and stirred for 15 min, then compound 11 (720 mg, 2.55 mmol, 1.0 eq) was added, and the reaction was allowed to proceed overnight at room temperature, and the reaction was monitored by TLC (DCM: MeOH = 20: 1). After the reaction was complete, the reaction solution was concentrated and purified by silica gel column chromatography (DCM: MeOH = 60: 1) to obtain compound 13a (white solid, 1.44 g, 86%). HRMS (ESI) predicted value C 36 H 51 N8O4 + [M+H] + : 659.4028, measured value: 659.4031.

[0037] (2) Specific preparation process of intermediate 14a:

[0038]

[0039] Compound 13a (1.00 g, 1.516 mmol) was dissolved in 4 mL of 4M hydrochloric acid / 1,4-dioxane and reacted at room temperature for 1 h to obtain compound 14a. The reaction solution was concentrated and used directly in the subsequent reaction.

[0040] (3) Specific preparation process of compound A2:

[0041]

[0042] Compound 14a (200 mg, 0.358 mmol, 1.0 eq) was dissolved in 4 mL of N,N-dimethylformamide, and then compound 7a (109 mg, 0.393 mmol, 1.1 eq) and N,N-diisopropylethylamine (138 mg, 1.074 mmol, 3.0 eq) were added. The mixture was reacted overnight at 90°C, and the reaction progress was monitored by TLC (DCM: MeOH = 15: 1). After the reaction was completed, the system was cooled to room temperature, and then 10 mL of water was added to the system, and EA was extracted (10 mL × 3). The organic phase was collected, and saturated sodium chloride solution was back-extracted (10 mL × 3). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, and purified by silica gel column chromatography (DCM: MeOH = 45: 1) to obtain compound A2 (yellow solid, 166 mg, 57%). HRMS (ESI) predicted value C 44 H 51 N 10 O6 + [M+H] +:815.3988, measured value:815.3978.

[0043] Example 3

[0044] A proteolysis targeting chimera (Compound A3), the synthesis route of which is as follows:

[0045]

[0046] The specific process is:

[0047] (1) Specific preparation process of intermediate 15a:

[0048]

[0049] Compound 12b (500 mg, 1.13 mmol, 1.0 eq) was dissolved in 6 mL 4M hydrochloric acid / 1,4-dioxane, and reacted at room temperature to remove Boc. After the reaction was complete, the reaction solution was concentrated, and then N,N-dimethylformamide (8 mL) and triethylamine (343 mg, 3.39 mmol, 3.0 eq) were added. Bromoacetyl chloride (186 mg, 1.187 mmol, 1.05 eq) was slowly added dropwise at 0°C, and reacted at 0°C for 30 min. The reaction progress was monitored by TLC (DCM: MeOH = 18: 1). After the reaction was complete, 20 mL of water was added to the system, and EA was extracted (15 mL × 3). The organic phase was collected and back-extracted with saturated sodium chloride solution (15 mL × 3). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. It was purified by silica gel column chromatography (DCM: MeOH = 50: 1) to obtain compound 15a (yellow solid, 283 mg, 54%). HRMS (ESI) predicted value C 19 H 20 BrN4O5 + [M+H] + :463.0612, 465.0592, measured values:463.0614, 465.0596.

[0050] (2) Specific preparation process of intermediate 13b:

[0051]

[0052] The synthesis method is the same as compound 13a, using N-Boc-piperazine (500 mg, 2.68 mmol, 1.0 eq) as the raw material, and undergoing amide condensation with compound 4 to obtain compound 13b (white solid, 1.34 g, 89%). HRMS (ESI) predicted value C 30 H 40 N7O4 + [M+H] +:562.3137, measured value:562.3140.

[0053] (3) Specific preparation process of intermediate 14b:

[0054]

[0055] Compound 13b (1.00 g, 1.78 mmol) was dissolved in 10 mL of 4M hydrochloric acid / 1,4-dioxane and reacted at room temperature for 1 h to obtain compound 14b. The reaction solution was concentrated and used directly in the subsequent reaction.

[0056] (4) Specific preparation process of compound A3:

[0057]

[0058] Compound 14b (230 mg, 0.5 mmol, 1.0 eq) was dissolved in 8 mL of N,N-dimethylformamide, triethylamine (151 mg, 1.5 mmol, 3.0 eq) and 15a (234 mg, 0.5 mmol, 1.0 eq) were added, and the reaction was carried out at room temperature for 4 h. The reaction progress was monitored by TLC (DCM: MeOH = 15: 1). After the reaction was completed, 20 mL of water was added to the system, and EA was extracted (15 mL × 3). The organic phase was collected and back-extracted with saturated sodium chloride solution (15 mL × 3). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. It was purified by silica gel column chromatography (DCM: MeOH = 45: 1) to obtain compound A3 (yellow solid, 270 mg, 64%). HRMS (ESI) predicted value C 45 H 51 N 11 O7 + [M+H] + :844.3890, measured value:844.3902.

[0059] Example 4

[0060] A proteolysis targeting chimera (Compound A4), the synthesis route of which is as follows:

[0061]

[0062] The specific process is:

[0063] (1) Specific preparation process of intermediate 16a:

[0064]

[0065] Compound 12b (1.00 g, 2.26 mmol, 1.0 eq) was dissolved in 10 mL 4 M hydrochloric acid / 1,4-dioxane, and reacted at room temperature to remove Boc. After the reaction was complete, the reaction solution was concentrated, and then N,N-dimethylformamide (15 mL), triethylamine (687 mg, 6.76 mmol, 3.0 eq) and tert-butyl bromoacetate (440 mg, 2.26 mmol, 1.0 eq) were added. The reaction was continued at room temperature for 2 h, and the reaction progress was monitored by TLC (DCM: MeOH = 20: 1). After the reaction was complete, 40 mL of water was added to the system, and EA was extracted (30 mL × 3). The organic phase was collected and back-extracted with saturated sodium chloride solution (30 mL × 3). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. It was purified by silica gel column chromatography (DCM: MeOH = 60: 1) to obtain compound 16a (yellow solid, 857 mg, 83%). HRMS (ESI) predicted value C 23 H 29 N4O6 + [M+H] + : 457.2082, measured value: 457.2085.

[0066] (2) Specific preparation process of intermediate 17a:

[0067]

[0068] Compound 16a (850 mg, 1.86 mmol) was dissolved in 8 mL of DCM, and then 8 mL of trifluoroacetic acid was added to react at room temperature overnight. After the reaction was complete, the solution was concentrated and used directly in the next step.

[0069] (3) Specific preparation process of compound A4:

[0070]

[0071] Compound 17a (200 mg, 0.50 mmol, 1.0 eq) was dissolved in 5 mL of N,N-dimethylformamide, and then HATU (228 mg, 0.60 mmol, 1.2 eq) and N,N-diisopropylethylamine (194 mg, 1.50 mmol, 3.0 eq) were added and stirred for 15 min, followed by addition of compound 14b (230 mg, 0.50 mmol, 1.0 eq) and reaction at room temperature overnight. The reaction progress was monitored by TLC (DCM: MeOH = 15: 1). After the reaction was complete, 15 mL of water was added to the system, and EA was extracted (10 mL × 3). The organic phase was collected and back-extracted with saturated sodium chloride solution (10 mL × 3). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. It was purified by silica gel column chromatography (DCM: MeOH = 45: 1) to obtain compound A4 (yellow solid, 219 mg, 52%). HR MS (ESI) predicted value C44 H 50 N 11 O7 + [M+H] + :844.3890, measured value:844.3896.

[0072] Example 5

[0073] A proteolysis targeting chimera (Compound A5), the synthesis route of which is as follows:

[0074]

[0075] The specific process is:

[0076] (1) Specific preparation process of intermediate 12c:

[0077]

[0078] Compound 7b (1.20 g, 3.56 mmol, 1.0 eq) was dissolved in 30 mL of N,N-dimethylformamide, and N-Boc-1,2,5,6-tetrahydropyridine-4-boronic acid pinacol ester (1.21 g, 3.915 mmol, 1.1 eq), potassium phosphate (1.89 g, 8.9 mmol, 2.5 eq) and bis(diphenylphosphino)ferrocenepalladium dichloride (261 mg, 0.356 mmol, 0.1 eq) were added in sequence. The argon gas was replaced three times, and then the reaction was carried out at 90 ° C overnight. The reaction was monitored by TLC (PE: EA = 1: 3). After the reaction was complete, 70 mL of water was added to the system, extracted with EA (50 mL × 3), the organic phase was collected, back-extracted with saturated sodium chloride solution (50 mL × 3), the organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, and purified by silica gel column chromatography (PE: EA = 1: 1) to obtain compound 12c (white solid, 1.19 g, 76%). HRMS (ESI) predicted value C 23 H 26 N3O6 + [M+H] + : 440.1817, measured value: 440.1821.

[0079] (2) Specific preparation process of intermediate 15b:

[0080]

[0081] Compound 12c (400 mg, 0.91 mmol, 1.0 eq) was used as the starting material and the synthesis method was the same as that of 15a to obtain compound 15b (white solid, 221 mg, 53%). HRMS (ESI) predicted value C 20 H 19 BrN3O5+ [M+H] + :460.0503, measured value:460.0506.

[0082] (3) Specific preparation process of compound A5:

[0083]

[0084] The synthesis method is the same as compound A3. Compound 15b (200 mg, 0.43 mmol, 1.0 eq) and 14b undergo nucleophilic substitution to obtain compound A5 (white solid, 223 mg, 61%). HRMS (ESI) predicted value C 45 H 49 N 10 O7 + [M+H] + :841.3781, measured value:841.3775.

[0085] Example 6

[0086] A proteolysis targeting chimera (Compound A6), the synthesis route of which is as follows:

[0087]

[0088] The specific process is:

[0089] (1) Specific preparation process of intermediate 19:

[0090]

[0091] Compound 12c (400 mg, 0.91 mmol, 1.0 eq) was dissolved in 10 mL MeOH, 10% palladium carbon (40 mg) was added, argon was purged five times, and then hydrogen was replaced five times. The reaction was allowed to proceed overnight at room temperature under a hydrogen atmosphere, and the reaction progress was monitored by TLC (PE: EA = 1: 3). After the reaction was complete, palladium carbon was filtered off with diatomaceous earth, and the filtrate was concentrated to obtain compound 19 (white solid, 379 mg, 95%). HRMS (ESI) predicted value C 23 H 28 N3O6 + [M+H] + : 442.1973, measured value: 442.1977.

[0092] (2) Specific preparation process of intermediate 15c:

[0093]

[0094] Compound 19 (350 mg, 0.79 mmol, 1.0 eq) was used as the starting material and the synthesis method was the same as compound 15a to obtain compound 15c (white solid, 186 mg, 51%). HRMS (ESI) predicted value C 20 H 21 BrN3O5 + [M+H] + : 462.0660, measured value: 462.0662.

[0095] (3) Specific preparation process of compound A6:

[0096]

[0097] The synthesis method is the same as compound A3. Compound 15c (150 mg, 0.32 mmol, 1.0 eq) and compound 14b undergo nucleophilic substitution to obtain compound A6 (white solid, 142 mg, 52%). HRMS (ESI) predicted value C 45 H 51 N 10 O7 + [M+H] + : 843.3937, measured value: 843.3934.

[0098] Example 7

[0099] A proteolysis targeting chimera (Compound A7), the synthesis route of which is as follows:

[0100]

[0101] The specific process is:

[0102] (1) Specific preparation process of intermediate 21:

[0103]

[0104] 2-Bromo-4'-nitroacetophenone (20) (1.00 g, 4.09 mmol, 1.0 eq) was dissolved in 40 mL of acetonitrile, and N-Boc-piperazine (839 mg, 4.5 mmol, 1.1 eq) was added. The mixture was reacted at room temperature for 1.5 h, and the reaction progress was monitored by TLC (PE: EA = 2: 1). After the reaction was complete, the reaction solution was concentrated and purified by silica gel column chromatography (PE: EA = 8: 1) to obtain compound 21 (orange-yellow solid, 1.23 g, 86%). HRMS (ESI) predicted value C 17 H 24 N3O5 + [M+H] + : 350.1711, measured value: 350.1714.

[0105] (2) Specific preparation process of intermediate 22a:

[0106]

[0107] Compound 21 (500 mg, 1.43 mmol, 1.0 eq) was dissolved in 14 mL MeOH, palladium carbon (50 mg) was added, and then argon was replaced five times, hydrogen was replaced five times, and the reaction was carried out at 0°C for 1 h. The reaction progress was monitored by TLC (PE: EA = 2: 1). After the reaction was complete, the mixture was filtered through diatomaceous earth, the filtrate was concentrated, and purified by silica gel column chromatography (PE: EA = 8: 1) to obtain compound 22a (white solid, 365 mg, 80%). HRMS (ESI) predicted value C 17 H 26 N3O3 + [M+H] + : 320.1969, measured value: 320.1965.

[0108] (3) Specific preparation process of intermediate 13c:

[0109]

[0110] The synthesis method is the same as compound 3a. Compound 22a (350 mg, 1.09 mmol, 1.0 eq) and compound 2 were subjected to Buchwald-Hartwig coupling to obtain compound 13c (white solid, 523 mg, 83%). HRMS (ESI) predicted value C 31 H 42 N7O4 + [M+H] + : 576.3293, measured value: 576.3297.

[0111] (4) Specific preparation process of intermediate 14c:

[0112]

[0113] Compound 13c (500 mg, 0.869 mmol, 1.0 eq) was dissolved in 6 mL of 4M hydrochloric acid / 1,4-dioxane solution, and after the reaction was complete, the solution was concentrated to obtain 14c, which was directly used in the subsequent reaction.

[0114] (5) Specific preparation process of compound A7:

[0115]

[0116] The synthesis method is the same as compound A3. Compound 14c (150 mg, 0.315 mmol, 1.0 eq) and compound 15a undergo nucleophilic substitution reaction to obtain compound A7 (yellow solid, 165 mg, 61%). HRMS (ESI) predicted value C 45 H 52 N 11 O7 + [M+H] + :858.4046, measured value:858.4040.

[0117] Example 8

[0118] A proteolysis targeting chimera (Compound A8), the synthesis route of which is as follows:

[0119]

[0120] The synthesis method is the same as compound A3. Compound 14a (150 mg, 0.268 mmol, 1.0 eq) and compound 15a undergo nucleophilic substitution reaction to obtain compound A8 (yellow solid, 154 mg, 61%). HRMS (ESI) predicted value C 50 H 61 N 12 O7 + [M+H] + :941.4781, measured value:941.4785.

[0121] Example 9

[0122] A proteolysis targeting chimera (Compound A9), the synthesis route of which is as follows:

[0123]

[0124] The synthesis method is the same as compound A4. Compound 14a (150 mg, 0.268 mmol, 1.0 eq) and compound 17a undergo amide condensation to obtain compound A9 (yellow solid, 121 mg, 48%). HRMS (ESI) predicted value C 50 H 61 N 12 O7 + [M+H] + : 941.4781, measured value: 941.4778.

[0125] Example 10

[0126] A proteolysis targeting chimera (Compound A10), the synthesis route of which is as follows:

[0127]

[0128] The specific process is:

[0129] (1) Specific preparation process of intermediate 15d:

[0130]

[0131] The synthesis method is the same as compound 15a. Compound 12a (1.50 g, 2.78 mmol, 1.0 eq) was reacted with bromoacetyl chloride after removing Boc to obtain compound 15d (yellow solid, 763 mg, 49%). HRMS (ESI) predicted value C 25 H 31 BrN5O5 + [M+H] + :560.1504, measured value:560.1506.

[0132] (2) Specific preparation process of compound A10:

[0133]

[0134] The synthesis method is the same as compound A3. Compound 15d (150 mg, 0.267 mmol, 1.0 eq) and compound 14b undergo nucleophilic substitution reaction to obtain compound A10 (yellow solid, 141 mg, 56%). HRMS (ESI) predicted value C 50 H 61 N 12 O7 + [M+H] + : 941.4781, measured value: 941.4778.

[0135] Embodiment 11

[0136] A proteolysis targeting chimera (Compound A11), the synthesis route of which is as follows:

[0137]

[0138] The specific process is:

[0139] (1) Specific preparation process of intermediate 23:

[0140]

[0141] Compound 12a (300 mg, 0.556 mmol, 1.0 eq) was dissolved in 6 mL of 4 M hydrochloric acid / 1,4-dioxane solution. After the reaction was complete, the reaction solution was concentrated, and then dichloroethane: MeOH (6 mL: 2 mL), compound 8 (130 mg, 0.611 mmol, 1.1 eq), glacial acetic acid (0.2 mL) and sodium triacetoxyborohydride (235 mg, 1.112 mmol, 2.0 eq) were added. The reaction was allowed to proceed overnight at room temperature, and the reaction was monitored by TLC (DCM: MeOH = 14: 1). After the reaction was complete, 15 mL of saturated sodium bicarbonate solution was added to the system at 0 ° C to quench the reaction, and DCM was extracted (20 mL × 3). The organic phase was collected, dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography (DCM: MeOH = 45: 1) to obtain compound 23 (yellow solid, 258 mg, 73%). HRMS (ESI) predicted value C 34 H 49 N6O6 + [M+H] + : 637.3709, measured value: 637.3712.

[0142] (2) Specific preparation process of compound A11:

[0143]

[0144] Compound 23 (200 mg, 0.313 mmol, 1.0 eq) was dissolved in 4 mL 4M hydrochloric acid / 1,4-dioxane solution, and the reaction solution was concentrated after the reaction was complete. Compound 4 (123 mg, 0.313 mmol, 1.0 eq) was dissolved in 4 mL N,N-dimethylformamide, HATU (143 mg, 0.376 mmol, 1.2 eq) and N,N-diisopropylethylamine (121 mg, 0.941 mmol, 3.0 eq) were added, and stirred at room temperature for 15 min, and then the above-mentioned Boc-free compound 23 was added, and the reaction was allowed to proceed overnight at room temperature, and monitored by TLC (DCM: MeOH = 9: 1). After the reaction was complete, 10 mL of water was added to the system, and EA was used for extraction (8 mL × 3). The organic phase was collected, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The organic phase was purified by silica gel column chromatography (DCM: MeOH = 30: 1) to obtain compound A11 (yellow solid, 123 mg, 43%). HRMS (ESI) predicted value C 50 H 62 N 11 O6 + [M+H] + :912.4880, measured value:912.4878.

[0145] Example 12

[0146] A proteolysis targeting chimera (Compound A12), the synthesis route of which is as follows:

[0147]

[0148] The specific process is:

[0149] (1) Specific preparation process of intermediate 24a:

[0150]

[0151] The synthesis method is the same as compound 10. Compound 14c (200 mg, 0.42 mmol, 1.0 eq) and compound 8 were subjected to reductive amination reaction to obtain compound 24a (white solid, 217 mg, 77%). HRMS (ESI) predicted value C 37 H 53 N8O4 + [M+H] + : 673.4185, measured value: 673.4186.

[0152] (2) Specific preparation process of compound A12:

[0153]

[0154] Compound 24a (200 mg, 0.297 mmol, 1.0 eq) was dissolved in 4 mL 4M hydrochloric acid / 1,4-dioxane. After the reaction was complete, the reaction solution was concentrated, and then N,N-dimethylformamide (4 mL), triethylamine (90 mg, 0.891 mmol, 3.0 eq) and compound 15a (137 mg, 0.297 mmol, 1.0 eq) were added. The reaction was allowed to proceed overnight at room temperature, and the reaction was monitored by TLC (DCM: MeOH = 9: 1). After the reaction was complete, 15 mL of water was added to the system, and EA was extracted (10 mL × 3). The organic phase was collected, and the saturated sodium chloride solution was back-extracted (10 mL × 3). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The organic phase was purified by silica gel column chromatography (DCM: MeOH = 30: 1) to obtain compound A12 (yellow solid, 164 mg, 58%). HRMS (ESI) predicted value C 51 H 63 N 12 O7 + [M+H] + :955.4938, measured value:955.4943.

[0155] Example 13

[0156] A proteolysis targeting chimera (Compound A13), the synthesis route of which is as follows:

[0157]

[0158] The specific process is:

[0159] (1) Specific preparation process of intermediate 22b:

[0160]

[0161] Compound 21 (500 mg, 1.43 mmol, 1.0 eq) was dissolved in 14 mL MeOH, palladium carbon (50 mg) was added, argon and hydrogen were replaced in turn, the reaction was allowed to proceed overnight at room temperature, and the reaction was monitored by TLC (PE: EA = 2: 1). After the reaction was complete, palladium carbon was filtered off and purified by silica gel column chromatography (PE: EA = 6: 1) to obtain compound 22b (white solid, 395 mg, 86%). HRMS (ESI) predicted value C 50 H 62 N 11 O6 + [M+H] + : 322.2126, measured value: 322.2129.

[0162] (2) Specific preparation process of intermediate 13d:

[0163]

[0164] The synthesis method is the same as compound 3a. Compound 22b (300 mg, 0.933 mmol, 1.0 eq) and compound 2 were subjected to Buchwald-Hartwig coupling to obtain compound 13d (white solid, 426 mg, 79%). HRMS (ESI) predicted value C 31 H 44 N7O4 + [M+H] + : 578.3450, measured value: 578.3447.

[0165] (3) Specific preparation process of intermediate 24b:

[0166]

[0167] The synthesis method is the same as compound 23. Compound 13d (200 mg, 0.346 mmol, 1.0 eq) was subjected to reductive amination with compound 8 after removal of Boc to obtain compound 24b (white solid, 182 mg, 78%). HRMS (ESI) predicted value C 37 H 55 N8O4 + [M+H] + : 675.4341, measured value: 675.4345.

[0168] (4) Specific preparation process of compound A13:

[0169]

[0170] The synthesis method is the same as compound A12. Compound 24b (150 mg, 0.222 mmol, 1.0 eq) was subjected to nucleophilic substitution reaction with compound 15a after removal of Boc to obtain compound A13 (yellow solid, 117 mg, 55%). HRMS (ESI) predicted value C 51 H 65 N 12 O7 + [M+H] + :957.5094, measured value:957.5100.

[0171] Embodiment 14

[0172] A proteolysis targeting chimera (Compound A14), the synthesis route of which is as follows:

[0173]

[0174] The specific process is:

[0175] (1) Specific preparation process of intermediate 11b:

[0176]

[0177] The synthesis method is the same as compound 11a. Compound 10b (1.50 g, 3.586 mmol) was deprotected from Cbz to obtain compound 11b (white solid, 965 mg, 95%). HRMS (ESI) predicted value C 15 H 30 N3O2 + [M+H]+: 284.2333, found: 284.2335.

[0178] (2) Specific preparation process of intermediate 26a:

[0179]

[0180] The synthesis method is the same as compound A4. Compound 11b (500 mg, 1.764 mmol, 1.0 eq) and compound 17a are subjected to amide condensation to obtain compound 26a (yellow solid, 893 mg, 76%). HRMS (ESI) predicted value C 34 H 48 N7O7 + [M+H] + : 666.3610, measured value: 666.3607.

[0181] (3) Specific preparation process of intermediate 27:

[0182]

[0183] The synthesis method was the same as compound 14a. After the reaction was complete, the reaction solution was concentrated and used directly in the subsequent reaction without further purification.

[0184] (4) Specific preparation process of compound A14:

[0185]

[0186] Compound 3b (200 mg, 0.49 mmol, 1.0 eq) was dissolved in 6 mL MeOH, and 2 mL aqueous solution containing LiOH (23 mg, 0.98 mmol, 2.0 eq) was added to hydrolyze the ester bond. After the reaction was complete, the pH was adjusted to neutral with 1 M aqueous hydrochloric acid solution, and N, N-dimethylformamide (6 mL), HATU (223 mg, 0.588 mmol, 1.2 eq) and N, N-diisopropylethylamine (127 mg, 0.98 mmol, 2.0 eq) were added, and compound 27 (276 mg, 0.49 mmol, 1.0 eq) was reacted at room temperature overnight. After the reaction was complete, 15 mL of water was added to the system, and EA was extracted (10 mL×3). The organic phase was collected, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by silica gel column chromatography (DCM: MeOH = 40: 1) to obtain compound A14 (yellow solid, 190 mg, 42%). HRMS (ESI) predicted value C 50 H 61 N 12 O7 + [M+H] + : 941.4781, measured value: 941.4778.

[0187] Embodiment 15

[0188] A proteolysis targeting chimera (Compound A15), the synthesis route of which is as follows:

[0189]

[0190] The specific process is:

[0191] (1) Specific preparation process of intermediate 28a:

[0192]

[0193] Compound 10b (500 mg, 1.197 mmol, 1.0 eq) was dissolved in 8 mL of 4M hydrochloric acid / 1,4-dioxane solution and reacted at room temperature for 30 min. The reaction progress was monitored by TLC (PE: EA = 1: 1). After the reaction was completed, the reaction solution was concentrated, and then acetonitrile (20 mL), trans-4-(tert-butyloxycarbonylaminomethyl)cyclohexylcarboxylic acid (308 mg, 1.197 mmol, 1.0 eq), HATU (546 mg, 1.437 mmol, 1.2 eq) and N,N-diisopropylethylamine (464 mg, 3.592 mmol, 3.0 eq) were added. The reaction was continued at room temperature for 6 h. The reaction progress was monitored by TLC (DCM: MeOH = 19: 1). After the reaction was completed, the reaction solution was concentrated and purified by silica gel column chromatography (DCM: MeOH = 60: 1) to obtain compound 28a (white solid, 580 mg, 87%). HRMS (ESI) predicted value C 31 H 49 N4O5 + [M+H] + :557.3698, measured value:557.3701.

[0194] (2) Specific preparation process of intermediate 29a:

[0195]

[0196] Compound 28a (500 mg, 0.897 mmol, 1.2 eq) was dissolved in 8 mL of 4M hydrochloric acid / 1,4-dioxane solution and reacted at room temperature for 30 min. The reaction progress was monitored by TLC (DCM: MeOH = 19: 1). After the reaction was complete, the reaction solution was concentrated. Then NMP (8 mL), compound 2 (218 mg, 0.747 mmol, 1.0 eq) and N,N-diisopropylethylamine (289 mg, 2.242 mmol, 3.0 eq) were added, and the mixture was refluxed at 140°C for 24 h. The reaction progress was monitored by TLC (DCM: MeOH = 15: 1). After the reaction was complete, the system was cooled to room temperature, and then 20 mL of water was added, EA was extracted (15 mL × 3), the organic phase was collected, and saturated sodium chloride solution was back-extracted (15 mL × 3). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, and purified by silica gel column chromatography (DCM: MeOH = 60: 1) to obtain compound 29a (white solid, 282 mg, 53%). HRMS (ESI) predicted value C 40 H 57 N8O4 + [M+H] + :713.4498, measured value:713.4496.

[0197] (3) Specific preparation process of compound A15:

[0198]

[0199] Compound 29a (260 mg, 0.364 mmol, 1.0 eq) was dissolved in 6 mL MeOH, and 30 mg of 10% palladium carbon was added. Argon and hydrogen were replaced in turn. The reaction was allowed to proceed overnight at room temperature under a hydrogen atmosphere and monitored by TLC (DCM: MeOH = 15: 1). After the reaction was complete, palladium carbon was filtered off, the filtrate was concentrated, and then 5 mL of N, N-dimethylformamide, compound 15a (168 mg, 0.364 mmol, 1.0 eq) and triethylamine (74 mg, 0.728 mmol, 2.0 eq) were added. The reaction progress was monitored by TLC (DCM: MeOH = 12: 1). After the reaction was complete, 15 mL of water was added to the system, and EA was extracted (10 mL × 3). The organic phase was collected, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The product was purified by silica gel column chromatography (DCM: MeOH = 40: 1) to obtain compound A15 (yellow solid, 196 mg, 56%). HRMS (ESI) predicted value C 51 H 69 N 12 O7 + [M+H] + :961.5407, measured value:961.5422.

[0200] Example 16

[0201] A proteolysis targeting chimera (Compound A16), the synthesis route of which is as follows:

[0202]

[0203] The specific process is:

[0204] (1) Specific preparation process of intermediate 28b:

[0205]

[0206] The synthesis method is the same as compound 28a. Compound 10b (400 mg, 0.958 mmol, 1.0 eq) was subjected to amide condensation with Bo c-trans-4-aminocyclohexanecarboxylic acid after removal of Boc to obtain compound 28b (white solid, 463 mg, 89%). HRMS (ESI) predicted value C 30 H 47 N4O5 + [M+H] + : 543.3541, measured value: 543.3544.

[0207] (2) Specific preparation process of intermediate 29b:

[0208]

[0209] The synthesis method is the same as compound 29a. Compound 28b (450 mg, 0.829 mmol, 1.2 eq) was subjected to nucleophilic substitution reaction with compound 2 after removal of Boc to obtain compound 29b (white solid, 260 mg, 54%). HRMS (ESI) predicted value C 39 H 55 N8O4 + [M+H] + : 699.4341, measured value: 699.4345.

[0210] (3) Specific preparation process of compound A16:

[0211]

[0212] The synthesis method is the same as compound A15. Compound 29 (200 mg, 0.286 mmol, 1.0 eq) was subjected to nucleophilic substitution reaction with compound 15a after removing Cbz to obtain compound A16 (yellow solid, 141 mg, 52%). HRMS (ESI) predicted value C 50 H 67 N 12 O7 + [M+H] + :947.5251, measured value:947.5260.

[0213] Embodiment 17

[0214] A proteolysis targeting chimera (Compound A18), the synthesis route of which is as follows:

[0215]

[0216] The specific process is:

[0217] (1) Specific preparation process of intermediate 32b:

[0218]

[0219] The synthesis method is the same as compound 32a. 1-Boc-4-aminopiperidine (2d) (410 mg, 2.049 mmol, 1.2 eq) and compound 1 are substituted to obtain compound 32b (white solid, 538 mg, 69%). HRMS (ESI) predicted value C 24 H 37 N6O3 + [M+H] + : 457.2922, measured value: 457.2925.

[0220] (2) Specific preparation process of compound A18:

[0221]

[0222] The synthesis method is the same as compound A11. Compound 32b (200 mg, 0.437 mmol, 1.0 eq) was subjected to amide condensation with compound 31 after removal of Boc to obtain compound A18 (yellow solid, 206 mg, 49%). HRMS (ESI) predicted value C 50 H 68 N 13 O7 + [M+H] + : 962.5360, measured value: 962.5361.

[0223] Embodiment 18

[0224] A proteolysis targeting chimera (Compound B1), the synthesis route of which is as follows:

[0225]

[0226] The specific process is:

[0227] (1) Specific preparation process of intermediate 15e:

[0228]

[0229] The synthesis method is the same as compound 15a. Compound 12d (400 mg, 0.91 mmol, 1.0 eq) was subjected to amide condensation with bromoacetyl chloride after removal of Boc to obtain compound 15e (yellow solid, 225 mg, 54%). HRMS (ESI) predicted value C 19 H 20 BrN4O5 + [M+H] + :463.0612, measured value:463.0615.

[0230] (2) Specific preparation process of compound B1:

[0231]

[0232] The synthesis method is the same as compound A3. Compound 15e (150 mg, 0.324 mmol, 1.0 eq) and 14a were subjected to nucleophilic substitution to obtain compound B1 (yellow solid, 167 mg, 55%). HRMS (ESI) predicted value C 50 H 61 N 12 O7 + [M+H] +: 941.4781, measured value: 941.4791.

[0233] Embodiment 19

[0234] A proteolysis targeting chimera (compound B2), the synthesis route of which is as follows:

[0235]

[0236] The specific process is:

[0237] (1) Specific preparation process of intermediate 16b:

[0238]

[0239] The synthesis method is the same as compound 16a. Compound 12d (300 mg, 0.678 mmol, 1.0 eq) was de-Bocated and reacted with tert-butyl bromoacetate to obtain compound 16b (yellow solid, 244 mg, 79%) by nucleophilic substitution. HRMS (ESI) predicted value C 23 H 29 N4O6 + [M+H] + : 457.2082, measured value: 457.2086.

[0240] (2) Specific preparation process of intermediate 17b:

[0241]

[0242] Compound 16b was used as the starting material and the synthesis method was the same as that of compound 17a, which was directly used in the next step.

[0243] (3) Specific preparation process of compound B2:

[0244]

[0245] The synthesis method is the same as compound A4. Compound 17b and 14a are subjected to amide condensation to obtain compound B2 (yellow solid, 169 mg, 48%). HRMS (ESI) predicted value C 50 H 61 N 12 O7 + [M+H] + :941.4781, measured value:941.4787.

[0246] Comparative Example 1

[0247] A proteolysis targeting chimera (Compound A17), the synthesis route of which is as follows:

[0248]

[0249] The specific process is:

[0250] (1) Specific preparation process of intermediate 26b:

[0251]

[0252] The synthesis method is the same as compound A3. Compound 11b (800 mg, 2.822 mmol, 1.0 eq) and compound 15a are subjected to nucleophilic substitution reaction to obtain compound 26b (yellow solid, 1.43 g, 76%). HRMS (ESI) predicted value C 34 H 48 N7O7 + [M+H] + : 666.3610, measured value: 666.3612.

[0253] (2) Specific preparation process of intermediate 30:

[0254]

[0255] The synthesis method is the same as compound 16a. Compound 26b (1.30 g, 1.95 mmol, 1.0 eq) was subjected to nucleophilic substitution reaction with tert-butyl bromoacetate after removal of Boc to obtain compound 30 (yellow solid, 1.03 g, 78%). HRMS (ESI) predicted value C 35 H 50 N7O7 + [M+H] + : 680.3767, measured value: 680.3764.

[0256] (3) Specific preparation process of intermediate 31:

[0257]

[0258] Compound 30 was used as the raw material, and the synthesis method was the same as that of compound 17a, which was directly used in the subsequent reaction without purification.

[0259] (4) Specific preparation process of intermediate 32a:

[0260]

[0261] Compound 1 (500 mg, 1.707 mmol, 1.0 eq) was dissolved in 15 mL NMP, and then (S)-1-Boc-3-aminopiperidine (2c) (410 mg, 2.049 mmol, 1.2 eq) and N,N-diisopropylethylamine (662 mg, 5.123 mmol, 3.0 eq) were added. The mixture was refluxed at 140 °C for 18 h, and the reaction progress was monitored by TLC (DCM: MeOH = 20: 1). After the reaction was completed, the system was cooled to room temperature, and then 40 mL of water was added, and EA was extracted (25 mL × 3). The organic phase was collected and back-extracted with saturated sodium chloride solution (25 mL × 3). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The organic phase was purified by silica gel column chromatography (DCM: MeOH = 60: 1) to obtain compound 32a (white solid, 506 mg, 65%). HRMS (ESI) predicted value C 24 H 37 N6O3 + [M+H] + : 457.2922, measured value: 457.2924.

[0262] (5) Specific preparation process of compound A17:

[0263]

[0264] The synthesis method is the same as compound A11. Compound 32a (200 mg, 0.437 mmol, 1.0 eq) was subjected to amide condensation with compound 31 after removal of Boc to obtain compound A17 (yellow solid, 189 mg, 45%). HRMS (ESI) predicted value C 50 H 68 N 13 O7 + [M+H] + :962.5360, measured value:962.5357.

[0265] Compound performance test

[0266] 1. Determination of compound cell activity

[0267] The 19 PROTAC molecules in Examples 1-19 and the 1 PROTAC molecule in Comparative Example 1 were evaluated by CCK-8 experiments; the in vitro antiproliferative activities of prostate cancer cell lines PC3 and DU145 were respectively evaluated. The highest concentration of PROTAC molecules was set to 10 μM, 3-fold gradient dilution, the lowest concentration was 0 μM, and a total of 10 concentration gradients were used. PC-3 and DU145 cells were incubated for 72 hours, respectively. The activity of cells was detected by MTT, and GraphPad Prism9 was used for data processing to calculate IC 50 The results are shown in Table 1:

[0268] Table 1 Antiproliferative activity of PROTAC molecules

[0269]

[0270]

[0271] Among them, +:>1000nM; ++:1000-100nM; +++:<100nM.

[0272] As shown in Table 1, all PROTAC compounds of Examples 1-19 have certain inhibitory activity on the selected PCa cell lines, especially on androgen-independent PC3 cells, while the PROTAC compound of Comparative Example 1 has lower activity. The activity of A1-A13 and B1-B2 was further evaluated on several other cell lines, and the results are shown in Table 2.

[0273] Table 2 Anti-proliferative activity of PROTAC molecules

[0274]

[0275] Among them, +:>100nM; ++:10-100nM; +:<10nM.

[0276] As shown in Table 2, it can be seen that most of the tested molecules have different degrees of inhibitory effects on MV-4-11, LNCap, Vcap and RM-1. The results show that the tested molecules have the potential to inhibit the proliferation of the above tumor cells.

[0277] 2. Determination of compound degradation activity

[0278] The degradation effect of some PROTAC compounds in Examples 1 to 19 on CDK2 / 4 / 6 / 9 proteins in PC3 cells was evaluated by Western Blot experiments. The levels of CDK2 / 4 / 6 / 9 proteins in cells were detected by Western Blot experiments, and it can be seen that these compounds have good degradation ability for CDK2 / 4 / 6 / 9 proteins.

[0279] Table 3 Determination of PROTAC molecules’ degradation activity against different CDKs

[0280]

[0281]

[0282] Among them, +++: >80%; ++: 50%-80%; +: <50%.

[0283] 3. Determination of CDKs kinase inhibition rate of compounds

[0284] HTRF kinase assay: The ADP-Glo ​​method was used to test the kinase activity, and the test concentrations of compound A12 and Ribociclib were set to 100 nM. The test results are shown in Table 4. Compared with Ribociclib, compound A12 significantly improved the inhibitory activity against CDK9 and CDK2, while maintaining a significant inhibitory effect on CDK4 / 6, and can effectively target CDK2 / 4 / 6 / 9 at the same time.

[0285] Table 4 Inhibition rate of compound A12 and Ribociclib on CDKs kinases

[0286]

[0287] Among them, ++++: >90%; +++: 70%-90%; ++: 50%-70%; +: <50%.

[0288] 4. Compound animal tumor inhibition experiment

[0289] In order to evaluate the anti-tumor ability of active PROTAC molecules in vivo, animal experiments on two xenograft tumor models in mice were performed (PC3, DU145). As shown in Table 5, PROTAC molecules exhibited anti-tumor activity, among which the PC-3 model had a more obvious inhibitory effect.

[0290] Table 5 Animal experiments

[0291]

[0292] The above is only a preferred embodiment of the present invention. The present invention is not limited to the above implementation. As long as the technical effect of the present invention is achieved by the same means, it should belong to the protection scope of the present invention. Within the protection scope of the present invention, its technical scheme and / or implementation method can have various modifications and changes.

Claims

1. A proteolysis targeting chimera, characterized in that Its structural formula is shown in Formula Ia or Formula Ib: The linker in the formula Ia is any one of the following structures: The Linker in Formula Ib is any one of the following structures:

2. The proteolysis targeting chimera according to claim 1, characterized in that Its structural formula is shown in A12:

3. A method for preparing the proteolysis targeting chimera according to claim 2, characterized in that: The synthetic route is as follows:

4. Use of the proteolysis targeting chimera or its solvate or pharmaceutically acceptable salt according to claim 1 or 2 in the preparation of a drug for treating and / or preventing cancer.

5. The use according to claim 4, characterized in that The cancer is prostate cancer.

6. A pharmaceutical composition, characterized in that The main active ingredient is the protein hydrolysis targeting chimera according to claim 1 or 2 or a pharmaceutically acceptable salt thereof.

7. The pharmaceutical composition according to claim 6, characterized in that The dosage form of the pharmaceutical composition is a liquid preparation or a solid preparation.

8. The pharmaceutical composition according to claim 7, characterized in that The dosage form is one of tablets, capsules, powders, granules, pills, pastes and powders.

9. The pharmaceutical composition according to claim 6, characterized in that The pharmaceutical composition also includes one or more pharmaceutically acceptable excipients or carriers.

10. The pharmaceutical composition according to claim 9, characterized in that The excipient includes at least one of a carbohydrate, a polymer, a lipid and a mineral.

Citation Information

Patent Citations

  • 3-aminopyrazine-2-formamide targeted protein hydrolysis chimera as well as preparation method, pharmaceutical composition and application of 3-aminopyrazine-2-formamide targeted protein hydrolysis chimera

    CN117024413A

  • Proteolysis targeting chimera as well as preparation method, pharmaceutical composition and application thereof

    CN117736187A

  • Proteolysis targeting chimera as well as preparation method, pharmaceutical composition and application thereof

    CN118005613A

  • Compound for inhibiting and degrading AuroraA as well as pharmaceutical composition and pharmaceutical application thereof

    CN118206558A

Cited By

  • Substituted pyrrolopyrimidine cyclin-dependent kinase 4 degraders

    WO2026217690A1